Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Infosys Limited (INFY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Infosys LimitedTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Infosys Limited vs Vertex Pharmaceuticals Incorporated — how do they compare? Infosys Limited trades at $12.4 (market cap $50.32B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.6× Infosys Limited's market cap, and Infosys Limited pays a 4.17% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.

INFYVRTX
Market Cap
$50.32B$132.79B
Sector
TechnologyHealth
52-Week High
$20.22$529.65
52-Week Low
$10.49$376.62
Enterprise Value
$48.07B$126.92B
Dividend Yield
4.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Infosys Limited

INFY trades at $12.53, up 1.38% today, with a bullish technical signal from moving averages. The company reported a Q1 2027 revenue miss but maintained strong operating margins of 21.1% and announced a CEO transition. Recent news highlights strategic AI collaborations, such as with Metsä Group and Sentara, driving digital transformation initiatives.

The outlook is mixed: robust profitability and AI growth offer upside, but lowered revenue guidance and competitive pressures pose risks. Analyst consensus is cautious with a $11.05 price target below the current price, suggesting limited near-term upside amid execution challenges.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.

Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.

Returns comparison

Trailing returns across standard periods

About Infosys Limited

Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.

Read more on INFY

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX